Hemocyanin-Keyhole Limpet (KLH) subunits, solution recombinant protein
KLH, keyhole limpett hemocyanin, hemocyanin, Megathura crenulata hemocyanin
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Concentration | 20 |
---|---|
Calculated MW | 350 and 390 kDa (Two main characteristic bands co-migrating with ferritin) |
Gene Symbol | KLH |
---|---|
Other Names | KLH, keyhole limpett hemocyanin, hemocyanin, Megathura crenulata hemocyanin |
Gene Source | Megathura crenulata |
Source | Megathura crenulata, Giant keyhole limpet |
Assay&Purity | MPLC-SEC; ≥ 95% |
Assay2&Purity2 | N/A; |
Recombinant | No |
Format | Liquid |
Storage | 2-8°C ; 20 mg/ml of clear dark blue liquid which may contain some particulate and fibers. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Hemocyanins are proteins that use copper binding sites to bind and transport oxygen in a variety of arthropods and mollusks. Hemocyanin is isolated from the hemolymph of the animals. Hemocyanin is one of the strongest antigens known. Hemocyanin has been in use as an immunological reagent for many years. It is used as a carrier protein for antibody production against antigens. Recent advances in immunology and the role immune system plays in diseases have opened a whole new era of product development activities aimed at developing novel therapeutics which is aimed at teaching the body's immune system to fight diseases like cancer, AIDS, etc. The approach involves the use of highly immunogenic molecule like the hemocyanin for non-specific immunostimulation (NSI) or active specific immunostimulation (ASI) using conjugate vaccines, wherein the tumor (disease) specific antigens are covalently bound to carrier protein like KLH and the product used in human clinical studies. Such products are termed “vaccines”. BioVision’s KLH subunits powder has major advantages associated with it, in terms of flexibility of use, the choice of buffer in early developmental studies and avoidance of issues associated with reconstitution of dry powder. These subunits are highly pure and have low endotoxin content.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.